Entering text into the input field will update the search result below

Zogenix gains 7% after FDA granted priority review to Fintepla application in LGS

Dec. 01, 2021 8:21 AM ETZogenix, Inc. (ZGNX)By: SA News Team

Doctor writing word Epilepsy with marker, Medical concept

Michail_Petrov-96/iStock via Getty Images

  • Zogenix (NASDAQ:ZGNX) perks up 7.3% premarket following an announcement that the FDA has accepted for filing and granted Priority Review to its supplemental New Drug Application (sNDA) for the use of Fintepla for the treatment of seizures

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.